uniQure Faces Class Action Lawsuit Amid FDA Criticism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy QURE?
Source: PRnewswire
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.770
Low
33.00
Averages
49.88
High
70.00
Current: 14.770
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed uncertainties regarding the BLA submission timeline for its AMT-130 drug, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statements Allegations: The lawsuit alleges that uniQure made misleading statements regarding its clinical trials and FDA submissions, failing to disclose critical adverse information that may have led investors to make uninformed decisions, thereby affecting their investment returns.
- Investor Action Recommendations: Affected uniQure investors are advised to apply by April 13, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and transparency in protecting investor interests.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., seeking damages for investors who purchased the company's securities between September 24, 2025, and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which could lead to misjudgments about the company's prospects and impact market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline due to the necessity for additional studies, with this omission potentially causing significant losses for investors.
- Investor Recovery Opportunity: Affected investors must apply by April 13, 2026, to be appointed as lead plaintiff to participate in potential recovery, indicating that legal avenues provide investors with a chance to recover losses and enhance oversight of corporate governance.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Notice: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades between September 24 and October 31, 2025, urging affected investors to contact the firm by April 13, 2026, to participate.
- False Statement Allegations: The complaint alleges that uniQure failed to secure full FDA approval for its pivotal study and misled the market regarding potential delays in its Biologics License Application (BLA) timeline, resulting in investor losses once the truth emerged.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, emphasizing the importance of timely action for investors to avoid becoming absent class members.
See More
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against uniQure N.V. (NASDAQ:QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the trading period from September 24, 2025, to October 31, 2025, with a deadline for participation by April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements regarding its pivotal study design, failing to achieve full FDA approval and underestimating potential delays in its BLA application, which materially misled investors during the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, noting that appointment as lead plaintiff is not a prerequisite for participation, thus providing broader access for investors to seek redress.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting some of the largest hedge funds and alternative asset managers as clients.
See More
Faruqi & Faruqi Encourages uniQure Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, indicating concerns over the company's legal liabilities.
- Investor Rights Reminder: The firm reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff, highlighting the opportunity for investors to participate in legal action and seek compensation.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support and consultation.
- Background of Securities Class Action: This investigation is related to a federal securities class action already filed against uniQure, reflecting market concerns over potential financial misconduct by the company, which could impact its stock price and investor confidence.
See More
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed uncertainties regarding the BLA submission timeline for its AMT-130 drug, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting investor disappointment in the company's prospects.
- False Statements Allegations: The lawsuit alleges that uniQure made misleading statements regarding its clinical trials and FDA submissions, failing to disclose critical adverse information that may have led investors to make uninformed decisions, thereby affecting their investment returns.
- Investor Action Recommendations: Affected uniQure investors are advised to apply by April 13, 2026, to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and transparency in protecting investor interests.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., seeking damages for investors who purchased the company's securities between September 24, 2025, and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure's executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approval, which could lead to misjudgments about the company's prospects and impact market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline due to the necessity for additional studies, with this omission potentially causing significant losses for investors.
- Investor Recovery Opportunity: Affected investors must apply by April 13, 2026, to be appointed as lead plaintiff to participate in potential recovery, indicating that legal avenues provide investors with a chance to recover losses and enhance oversight of corporate governance.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Notice: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades between September 24 and October 31, 2025, urging affected investors to contact the firm by April 13, 2026, to participate.
- False Statement Allegations: The complaint alleges that uniQure failed to secure full FDA approval for its pivotal study and misled the market regarding potential delays in its Biologics License Application (BLA) timeline, resulting in investor losses once the truth emerged.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, emphasizing the importance of timely action for investors to avoid becoming absent class members.
See More
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against uniQure N.V. (NASDAQ:QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the trading period from September 24, 2025, to October 31, 2025, with a deadline for participation by April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements regarding its pivotal study design, failing to achieve full FDA approval and underestimating potential delays in its BLA application, which materially misled investors during the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, noting that appointment as lead plaintiff is not a prerequisite for participation, thus providing broader access for investors to seek redress.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting some of the largest hedge funds and alternative asset managers as clients.
See More
Faruqi & Faruqi Encourages uniQure Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, indicating concerns over the company's legal liabilities.
- Investor Rights Reminder: The firm reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff, highlighting the opportunity for investors to participate in legal action and seek compensation.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support and consultation.
- Background of Securities Class Action: This investigation is related to a federal securities class action already filed against uniQure, reflecting market concerns over potential financial misconduct by the company, which could impact its stock price and investor confidence.
See More
